2024 Speakers

Dr. Richard Adair obtained his Honours degree in Immunology in 1994 from the University of Edinburgh. For the following four years he worked as a Clinical Research Manager for Procter & Gamble Technical Centres Ltd. based in Staines, but undertook management of clinical research trials in...

Professor Tim Aitman is Director of the Centre for Genomic and Experimental Medicine and Professor of Molecular Pathology and Genetics at the University of Edinburgh, and Consultant Physician in NHS Lothian. He is a Fellow of the Royal Society of Edinburgh, and of the Royal Colleges of Physicians...

Ana Filipa is a seasoned market access professional with over 18 years of experience in launching products across diverse therapeutic areas and in building and leading high-performing international teams. She holds a PharmD from the University of Lisbon, a Master’s in Public Health from the London...

LAV (MD, PhD) graduated in Medicine from the University of Oviedo (Asturias, Spain). He completed a Medical Residency in Immunology and obtained his PhD in Immunology (1993) at the Autonomous University of Madrid, working on T cell development in the human thymus. He completed a three-year...

Baptiste Balbuena is a Biomanufacturing Engineer MSAT EMEA passioned by bioprocessing. Holder of a master’s degree in project management and biotechnologies innovation from Montpellier University, he dedicated last years to technically support customers with various problematics concerning...

Justyna is a Senior Team Leader in the Biological Assays Laboratory, where she is responsible for the development, transfer and validation of bioassays, as well as batch release testing of biological drugs.She’s been working at Selvita for the past 9 years. Justyna is a graduate of Biotechnology at ...

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Philip is CSO at Step Pharma, a French therapeutic biotech focused on novel targeted approaches for the treatment of cancer. Prior to joining Step Pharma, Philip held senior leadership roles in biotech and biopharma companies, overseeing oncology drug development and biomarker discovery...

Dr. Nicola Beltraminelli joined Innate Pharma as Vice President and Chief Development Officer in January 2022 and was recently appointed as Head of Reasearch Early Development of the organization. Dr. Beltraminelli brings 25 years of biotech experience to the role, and specifically in the...

Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy...

Thierry Besson obtained his master’s degree in analytical chemistry at the University of Rennes – France in 2005. I always used mass spectrometry in the different laboratories I joined, starting at Servier for the structure elucidation of small molecules, then in a fundamental lab research facility ...

Phil has over 20 years’ experience in biopharmaceutical R&D and has held senior operational and leadership roles in the development of novel antibody therapeutics. He began his career at the Glaxo Institute of Applied Pharmacology and GlaxoWellcome before gaining biologics expertise at...

Oliwia is an Analytical Expert in the Development and Contract Testing Department at Selvita, where she is responsible for the comprehensive protein and peptide characterization, as well as the development, and validation of analytical methods using high-resolution mass spectrometry-based...

Thomas Bols is PTC Therapeutics’ Head of Government Affairs and Patient Engagement, EMEA & APAC.  Thomas joined PTC in March 2020, continuing his career in the biopharmaceutical industry, having held positions for Amgen, Merck, Biogen and, most recently, at the global association, DIA.  He has ...

Sara Bonetti is Senior Scientist at Salipro Biotech, a company located in Stockholm, Sweden, working on stabilizing challenging drug targets for drug discovery. Prior to joining Salipro Biotech, Sara obtained her PhD in Biochemistry and Molecular Biology from the University of...

Dr. Tanima Bose, Analytical lead, MS&T lab, Kundl, Austria   Tanima Bose has been working in the field of immunology for almost 15+ years. After finishing her PhD in the interaction of ion channels in immune cells from Leibniz Institute for Neuroimmunology in collaboration with the Clinical...

Role​ CEO & Founder of Genchrome Limited, a leading European Healthcare Consulting company.​   Background. ​ Born and educated in France, after completing a Pharmacy Degree, she started her career as a Hospital Pharmacist in Paris before moving to the pharmaceutical Industry.​   Advising...

Jerome Boyd-Kirkup has served as our Chief Scientific Officer since co-founding Hummingbird Bioscience in 2015, and served on our Board of Directors from 2015 to 2021. Between 2011 and 2015 Dr. Boyd-Kirkup held the position of Young International Fellow in Molecular Systems Biology at the CAS-MPG...

Diego has more than two decades of venture capital experience and has developed a solid experience in creating, growing and exiting ventures in therapeutics and medical devices. He served as chairman and non-executive director in Endoart (acquired by Allergan), Endosense (acquired by St...

Professor Brockwell is an academic in the School of Molecular and Cellular Biology and a member of the Astbury Centre at the University of Leeds in the UK.  He undertook his undergraduate studies (Pharmacy) and PhD at the University of Manchester, before joining Leeds first as post-doctoral...

Craig Burton is the Senior Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines and the Executive Director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the...

Ursula is currently leading Regulatory Affairs for Tigen Pharma, a Swiss biotech company developing autologous T-cell therapies against cancer. Ursula joined Tigen from Boehringer-Ingelheim, where she was Head of Regulatory Intelligence & Policy. Prior to that, Ursula worked at Novartis as...

•Ex-Harvard fellow •Over 15-years of experience in Vaccine technology, Oncology and RNA biology •Raised more than 1 million GBP in understanding role of mRNA in cancer in academic •Lead successful oncology projects in Academics and Industry Reviewer, Speaker and CHAIR of many scientific...

Patrick Chames obtained his phD at the "University de la Méditerranée", Marseille, France in 1997 in the field of antibody engineering. From 1997 to 2001, he worked in the laboratory of phage display pioneer Hennie R. Hoogenboom where he isolated by phage display the first human antibody...

Mimi’s vision is to improve access to medicines for patients by harnessing the power of collaborations to mobilize resources to help our societies get access to medicines through the 4As, availability, accessibility, affordability, and acceptability.Since 1990, she has committed herself as an...

Thomas Cornell gained his Ph.D. from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Tom has gained...

Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she collaborates to the "Antibodies to watch" editorials in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody...

Roberto Di Niro is a molecular biologist and immunologist, with a PhD from the University of Trieste, Italy. He has more than 15 years of experience in scientific research, primarily in the field of antibody engineering. Before joining Specifica, Roberto was a postdoctoral research at the...

Gundo Diedrich is Executive Director of Antibody Engineering at MacroGenics. His work focuses on the discovery, engineering, and expression of antibodies as well as the development of the company’s multispecific antibody platform. Gundo received a Ph.D. in Chemistry from the Max-Planck Institute...

With over 12 years of experience in protein expression, purification, and biophysical characterization, I am a biochemist passionate about lab automation and the integration of AI and machine learning in the daily life of researchers. As the Head of Biology at Cinference, I lead a team of...

Patrick Doonan PhD is the director of antibody engineering at Ailux.  He brings over a decade of industry experience in the field of antibody drug discovery from target ID to FIH. His tenure at Pfizer and JNJ generated several high impact publications and patents furthering efforts in...

Stefan Dübel is Full Professor of Biotechnology and Director of the corresponding department at the Technical University of Braunschweig, Germany. After completing his PhD at the University of Heidelberg, he joined the German Cancer Research Center (DKFZ) in 1989, where he pioneered in vitro...

Lindy is Professor of Cancer Immunotherapy and CEO of Scancell Ltd. She has developed two vaccine platforms ImmunoBody® and Moditope®which induce potent killer CD8 T cells and cytotoxic CD4 T cells respectively. The first ImmunoBody®, SCIB1, has completed a phase I/II monotherapy clinical trial in...

David Falck studied Chemistry at the University of Münster, Germany, and obtained his PhD in the Biomolecular Analysis group of Profs. Hubertus Irth and Wilfried Niessen at the VU University Amsterdam, Netherlands. Since 2013, he works at the Center for Proteomics and Metabolomics, Leiden...

I am leading Protein Expression Technologies team at GSK R&D hub in Stevenage, UK. We use automation and HT methodologies to streamline delivery of protein reagents for early drug discovery projects, for both small and large molecule modalities. I have moved to GSK in 2018 after successful...

I am a researcher in Translational Modelling & Simulation at Roche. I support large molecule projects through model-based predictions that e.g. support the optimization of compound dosing schedules, predict First-In-Human dosing or select a lead drug candidate. I also develop in silico models...

Dr. Margaux Fresnais obtained her PhD of chemistry at the University of Strasbourg (France) in 2016. Since then, she dedicated her activities to the development of mass spectrometric (MS) methods for targeting therapeutic antibodies and small-compound pharmaceuticals for personalized medicine. She...

Ettore Gilardoni is Head of Mass Spectrometry at Philochem AG. The team main activities vary from biodistribution of small organic molecules in biospecimens; biopharmaceuticals characterization, and proteomics application for target identification; host cell proteins characterization, and mechanism ...

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in ...

Professor Torbjörn Gräslund holds a Ph.D. in Biotechnology from KTH - Royal Institute of Technology, Sweden, since 2001. After two years of post-doc training with Professor Carlos Barbas at the Scripps Research Institute, he has been principal investigator at the Department of Protein Science at...

Dr. Sherry Gu joined WuXi Biologics in 2017 and built a strong CMC Management team in the US and EU. With over 27 years of biopharmaceutical industry experience, Dr Sherry Gu has extensive expertise in cell line, upstream and downstream development and portfolio management. She served leadership...

Prateek has over 15 years of experience, including international leadership roles in global biopharmaceutical companies in product development and manufacturing of novel biologics (NBE) and biosimilars. Prior to Stelis, he was Senior General Manager and Head of Process Science at Intas...

Livnat Halel Buhnik is a senior clinical project manager at Cerebral therapeutics inc. as a Project manager, responsible for complex projects, which require integration of different professions, development, regulatory affairs, quality, laboratory, production and validation Livnat has many years...

Anissa Harbi is an Immunologist MD from Annaba, Algeria, with a strong background in clinical research and patient care. Currently serving as an Immunologist at Les Hôpitaux d'Alger, Anissa is dedicated to advancing medical knowledge and improving patient outcomes.

​​​​​​​Emma Harding graduated from Nottingham University with a Chemistry degree and a Biophysics PhD. This was followed up by a post doc in the Technical University of Munich, studying protein folding, before joining GSK in 2008. Here, her initial work was focussed on establishing developability...

After a Post Doc in Cambridge, Barbara held positions in Drug Discovery at GSK, Stevenage, UK and Boehringer Ingelheim, Vienna, Austria covering Virology, Autoimmunity and Inflammation and later Oncology. She then gained CRO experience in CMC Services leading a team of Bioassay Scientist developing ...

since 2020: Senior Application Scientist Sartorius  2019-2020: Senior Application Scientist FortéBio by Molecular Devices 2013-2019: (Senior) Application Scientist Pall FortéBio 2008-2013 PhD thesis: "Development of Ultra High Troughput Screening Methods for Combinatorial Oxidase- and...

Jana is the head of Corporate Scientific Engagement at Genedata, where she works with customers and partners to build and implement their data strategies into the biopharma R&D value chain. Over the last 20 years, she has held positions in both academia and industry on leveraging...

Youssef Hijazi is an expert in pharma R&D. He is currently employed as a distinguished scientist in pharmacokinetics at Sanofi-Aventis GmbH in Germany. He is a pharmacist by training and holds a PhD degree in pharmacokinetics from Claude Bernard University of Lyon. Youssef Hijazi has more than...

Jeroen Hofenk is the Founder and Chief Science Officer of SwiftPharma, a CDMO startup company focused on democratizing the production of biologics through plant molecular farming.  Jeroen holds a double masters degree in molecular biology and genetics, and has +15 years of experience in the field...

Philipp Holliger, Ph.D. is Program Leader and Joint Head of PNAC Division at the MRC Laboratory of Molecular Biology (MRC LMB) in Cambridge, UK. Phil graduated from ETH Zürich and then moved to Cambridge for a Ph.D. and a postdoctoral fellowship with Nobel laureate Sir Greg Winter before joining...

Sebastian Hörner joined BiconY Therapeutics as a Senior Scientist in 2023. He studied technical biology at the University of Stuttgart from 2011 to 2017, where he started his work in the field of recombinant antibodies in the lab of Roland Kontermann. From 2017 to 2021, he worked as a PhD candidate ...

Dr. Huang joined HuniLife in 2018 and works on preclinical development of the first-in-class enolase-1 monoclonal antibody programs. Dr. Huang received her PhD from National Cheng Kung University, Taiwan. Her postdoctoral training at Virginia Commonwealth University, USA, involved investigation of...

James has over 15 years’ experience focusing on the formulation sector. Working at Croda he has focused on utilising Croda Pharma’s range of excipients and bioprocessing aids used in pharmaceutical formulations and processes. Previously, James led the new surfactant and formulation development...

Christel Iffland is Senior Vice President of Antibody Technologies at OmniAb. Dr. Iffland joined the OmniAb team and Ligand Pharmaceuticals in 2017 from Merck KGaA/EMD Serono where she previously served as Associate Director of Antibody Technologies, a Senior Scientist of Phage Technologies and...

Originally from Canada, Melita Irving began working in the field of T-cell engineering for cancer immunotherapy in Switzerland in 2007, and is a group leader at the Ludwig Institute for Cancer Research in the Department of Oncology at the University of Lausanne since 2013. Dr. Irving’s research is...

Rüdiger Jankowsky, Ph.D. is a seasoned life science entrepreneur with broad experience in product development and licensing in the biotech and healthtech industry. He served as CEO for several start-ups, built interdisciplinary expert organizations for R&D and licensing and was instrumental in...

Rubin Jiang, director of antibody process development & MSAT group of ProBio. Rubin has been working in large molecule process development area for 11 years. Before joining ProBio, Rubin served in process development positions with multiple Chemistry, Manufacturing, and Controls (CMC)...

Bruno Jolain  Portfolio and Strategy Lead  Health Equity and Population Science  F.Hoffmann-La Roche Ltd (Basel)   Academic Qualifications:  -Medical Doctorate, Rene-Descartes University (France)  -Diploma Pharmaco-epidemiology, McGill University (Canada) -BSC Computer Science, Paris    ...

Masters in political science from the University of Copenhagen 45 years of professional experience, including: Head of section in the Ministries of Social Affairs and of LabourLabour Counsellor at the Danish UN-mission in GenevaHealth Counsellor at the Danish EU-representation in BrusselsSpokesman ...

I am an antibody discovery and assay enthusiast. I joined Bayer (Wuppertal, Germany) in 2022 as a Lab Head in the Biologics Research Portfolio & Assay group, and right now focus on the antibody lead identification and characterization as a Matrix Lead in Antibody Screening & Assay...

Inventor of the P5 Platform to generate stable ADCs during Phd with Prof. Christian HackenbergerJoint Tubulis as Co-Founder in 2019Leads Tubulis Chemistry and Early Discovery efforts as VP

Dr. Hans Keirstead is an internationally recognized stem cell expert and successful entrepreneur. Known for developing treatments for quadriplegic spinal cord injury, cancer therapies for melanoma, brain, and ovarian cancers, and a multi-pathogen vaccine, he has also advanced therapeutic research...

Harald Kolmar is full professor at the TechnicalUniversität Darmstadt, Germany where he heads since 2005 the Department of Applied Biochemistry. He holds a Ph.D. and habilitation in biochemistry and molecular biology. His current scientific interests mainly focus on protein engineering and...

Bertolt is an expert in cancer drug discovery with 20 years of pharmaceutical industry experience and a broad background in oncology research covering target validation, biologics and small molecule lead discovery, as well as research supporting pre-IND, early and late-stage clinical development...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research. For the last 19 years Dan has been working with analytical development in the biopharmaceutical...

David Laine is an immunologist specialised in B cell biology with a PhD from École normale supérieure de Lyon, France. Before joining the antibody generation group at Teva 10 + years ago, David was a postdoctoral research at the Walter and Eliza Hall and at Latrobe University in...

Mayra Latorre-Martinez currently works at Swissmedic, in the Department of Clinical Trials where she is responsible for the evaluation and authorization of Clinical Trials. She is also Swissmedic representative at the Access Consortium Clinical Trials Working Group. Mayra worked at the Regulatory...

Heinz Läubli is a physician scientist with clinical training and a specialisation in Medical Oncology and Internal Medicine. He is a Professor for Cellular Cancer Immunotherapies at the University Hospital Basel, heading the Laboratory for Cancer Immunotherapy and leading the GMP...

Victor Le received the PhD degree in analytical chemistry from the University of Paris Saclay, Orsay, France, in 2019. He is currently a Postdoc in Novartis to develop the LC-MS Multi Attribute Method to monitor the potential quality attributes of therapeutic proteins. His research interests focus...

Professor Hong Liang earned his MS in Physics from The Chinese University of Hong Kong, followed by a PhD from the Department of Polymer Science at the University of Akron, USA. He then spent several years as a postdoctoral fellow at Oak Ridge National Laboratory in the United States.Since...

Since 2022, Giuseppe Licari has served as a Lead Scientist in Computational Structural Biology within the Global Drug Product Development department at Merck KGaA. His work focuses on establishing computational platforms for the characterization and screening of biological molecules, as well as...

Britta Lipinski is a PhD candidate in the Antibody Discovery and Protein Engineering Department of Merck KGaA, supervised by Stefan Zielonka, where she works in close collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research focuses on the...

Dr. Rémi Longuespée obtained a PhD in Life Sciences at the University of Lille (France) and a PhD of Biochemistry at the University of Sherbrooke (Canada) in 2012. He dedicated a major part of his career to the development of methods in mass spectrometry for applications in clinics, from anatomical ...

Angelica Loskog is the CEO of Lokon Pharma and a Professor of immunotherapy at Uppsala University in Sweden. Further, she is a scientific advisor to the venture capital company Nexttobe AB and is a board member of several of their portfolio companies and also a board member of Medivir AB (Publ). Dr ...

Robin Löving, Chief Scientific Officer (CSO) at Salipro Biotech. Robin has more than 15 years’ experience working with therapeutically interesting membrane proteins. He did his PhD with a focus on membrane proteins and antigen design at the Karolinska Institute in Stockholm, Sweden. After being...

Jeremy Loyau is Associate Director at Ichnos Glenmark Innovation responsible for the antibody discovery and optimization leading to the development of novel bi- or tri- specific immune engager therapeutics for cancer immunotherapy. He has led the implementation of Ichnos’ common light chain...

Director Biosimilars Policy & Science - Medicines for Europe  Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objective of the Biosimilar Medicines Group...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

Aimee Mattei, MS. is the Director of Bioinformatics at EpiVax. She manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects. She leads the development of novel in silico methods and tools for...

Raj is a serial entrepreneur with passion for identifying, launching and nurturing spin-out companies with over 20 years track record of building lasting partnerships. Raj currently serves as CEO and NED of Adendra Therapeutics, a company he co-founded as Entrepreneur in Residence at Apple Tree...

Clive Metcalfe is a principal scientist in monoclonal antibody therapies at the MHRA science campus.  His team focuses on all aspects of the safety and efficacy of mAb therapies from developing international reference standards to public health research aiming to make these treatments more...

Since 2024, Lorenzo has worked as an independent advisor, collaborating with national governments and international organizations to promote partnerships for medicine development and strengthen regulatory systems. Previously, he led the work on access to innovative treatments and technologies at...

Gustavo Schmidt Moreira is a Brazilian researcher with over 10 years of experience and more than 35 publications, primarily focusing on applied immunology. During his bachelor's and master's degrees at the Universidade Federal de Pelotas in Brazil, he conducted projects on monoclonal...

Aurore Morello holds a PhD in Immunology and bispecific targeted immunotherapy for cancer treatment and transplantation (Immunoconcept Bordeaux France), After her PhD, she performed a post doc at the Memorial Sloan Kettering Cancer center (MSKCC, New York) in the laboratory of Dr Adusumilli...

Andre is the Marketing Manager for Biologics Solutions at Unchained Labs supporting the development of new biologic and gene therapy drugs. His expertise covers fluorescence, static light scattering, and dynamic light scattering for biophysical characterization of proteins and viral vectors. His...

Cecil Nick, Vice President (Technical), at PAREXEL has been working in regulatory affairs and clinical development for over 40 years; mosly focused on biological medicines. Cecil Nick has particular expertise in vaccines, monoclonals and biosimilars, and has engaged in over 100 interactions and...

Björn Niebel is a Senior Principal Scientist, Lab Head in the Discovery Department of the Nanobody Research Platform at Sanofi Ghent. Björn received his master’s degree in Chemistry from the University of Braunschweig, Germany in 2006 and holds a PhD in Biochemistry from the University of...

Sebastian Oehler is a biochemist and DEL expert dedicated to discovering new drugs. He studied Life Science at the University of Konstanz to learn about drug discovery and development at the Imperial College in London and further deepen his knowledge in applied drug discovery during his Ph.D. at...

Aline de Almeida Oliveira holds a Bachelor's degree in Biological Sciences from the State University of Rio de Janeiro (2004), a Master's degree (2007), and a PhD (2011) in Oncology from the National Cancer Institute. She currently works at Bio-Manguinhos at Fiocruz, where she works at the...

Eliud Oloo is a Sr. Principal Scientist at Schrödinger and serves as Product Manager for the biologics modeling software suite.  Prior to his current role, he was a scientist at Sanofi R&D groups in Toronto and Boston where he led structure-based design of vaccines targeting a wide variety of...

Anikó Pálfi is Director Biochemistry and Cell Biology at Heidelberg Pharma Research GmbH, a pharma company located near Heidelberg (Germany), mainly conducting research and development of anti-cancer drugs. She obtained her bachelor’s degree in bioscience at the University of Heidelberg in 2012 and ...

Lewis is currently an advanced research fellow at the University of Aberdeen where he completed his PhD. In partnership with TauRx Therapeutics Ltd. and the Scottish Biologics Facility, his research is involved in the discovery and development of novel anti-tau therapeutics, immunodiagnostics and...

Mario is a Director of Technologies & Business Development at ATUM, with over 14 years of expertise in recombinant protein expression. He earned his PhD in Biotechnology from the University of Manchester, focusing on transcriptional mechanisms in CHO cells. Mario's career spans roles at...

Isabelle Petit Topin is a passionate professional for Protein biochemistry and all that has to do with protein in general. Graduated at the University Paris Diderot, Isabelle obtained her PhD in 2009 (CIFRE HRA Pharma - Inserm - Paris) in Protein Biochemistry and Crystallography. After her...

Dr. Simon Plyte has over 20 years’ experience in research and development in the Pharma industry, both in Big Pharma and small Biotech. He has worked on the discovery and development of NCEs and Biologics, predominantly in the field of Oncology but has also worked in...

Philipp Probst is Associate Director of ADC Research at Araris Biotech AG, a Swiss biotech company located in Au ZH pioneering a novel linker technology for antibody-drug conjugates. He studied Pharmaceutical Sciences and received his PhD from ETH Zürich in 2018, where he worked in the group of...

Holding an engineer degree in Biotechnology, back in 2000, since then, he spent last 23 years supporting pharmaceutical industry to provide safe and efficient treatments to patient. He started his career in the process with Pierre-Guerin (for those who remember Biolafitte bioreactors!), and moved...

I am heading a research group at the department of Protein science at the KTH School of Engineering sciences in Chemistry, Biotechnology and Health. We are a young group with four great PhD students, two excellent technicians, one extraordianary fantastic labmanager and two researchers. Our...

Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing...

Giulio earned his PhD in Biotechnology from the University of Technology Braunschweig working on ER-intrabodies and antibody phage display. This was followed by postdoctoral work on antibody engineering for improved affinity and developability. In this period he contributed to found and grow a...

Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany.  Since then, he held positions of increasing responsibility in the R&D departments of...

Paul studied chemistry at the university of Karlsruhe with a specialization in organic synthesis. After completing his Ph.D. in organic chemistry at the Karlsruhe Institute of Technology, Paul Sauter moved to the European Molecular Biology Laboratory for postdoctoral studies to advance...

Simone Schmitt has over 13 years of experience in antibody development and discovered more than 5 best-in-class antibodies. Pior to building the microfluidic high-troughput B cell cloning and screening platform at Memo Therapeutics she worked at Delenex Therapeutics. Simone holds a PhD in...

Felix Schumacher holds a BSc and MSc in Biochemistry from the Technical University of Munich and a PhD in Chemical Biology from the University College London. He is co-founder of Thiologics, a small London-based biotech company that works in the field of bioconjugation. He joined Roche pRED in 2013 ...

El-houcine Sebbar, MD, PhD, is currently serving as an Assistant Professor of Medical Biochemistry at the Faculty of Medicine and Pharmacy, Mohammed First University in Oujda, Morocco. His professional journey is driven by a passion for integrating medicine and biochemistry to advance...

Monique is passionate about advancing the discovery of biological therapeutics and diagnostics for better human health. She has a strong background in proteomics and machine learning, and how they can be applied to address complex discovery, and research challenges. As a senior scientific sales...

Caibin Sheng is a data scientist at GV20 Therapeutics, specializing in AI-driven drug discovery and development. He holds a Ph.D. in systems biology from Humboldt University Berlin, where he focused on modeling high-throughput single-cell imaging data. During his postdoctoral fellowship at...

Lei Shi, PhD. is an SVP at Biointron. Prior to that, he worked for a series of biotech companies, including Virtuoso Therapeutics, Zai Lab, and Bird Rock. Lei had also worked at J&J in antibody discovery technology. He completed his Postdoc study at MGH and Harvard Medical School.

Dr. Elena Shvets is a group leader of the Application Development Team at Sphere Fluidics Ltd., an innovative company utilizing microfluidics, i.e. picodroplet technology, to develop automated platforms for single cell screening and isolation. After finishing her PhD at the Weizmann Institute of...

Oliver Seifert is a senior scientist in the laboratory of Roland Kontermann at the University of Stuttgart and leads the bispecific antibody group. He is an expert in the field of antibody engineering with more than 20 years experience. His scientific research covers development and...

The Global Head for Pricing and Tender Excellence for Plasma Derived Therapies (PDT). Responsible for bringing innovations to patients across all global markets - U.S.A., Japan, EUCAN, and GEM. The Head of Pricing & Tender Excellence is a pivotal role that develops and executes company’s global ...

Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at BrickBio, Abveris, MassBiologics and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious ...

As the inventor of the Araris ADC Technology, Philipp has a profound background in Bioconjugation and ADCs. He was the founding CEO since the inception of Araris in 2019 securing $40M in financing from Swiss, UK, US and Korean investors and $2.5M non-dilutive financing from the Swiss Accelerator...

Mats Sundgren, PhD, MSc, is a distinguished authority in Health Data Strategy, serving both industry and academia. With an impressive career spanning over 37 years in the pharmaceutical industry, Mats has made significant contributions across various domains, including...

Prof. Dr. Oya Tagit obtained her PhD at the MESA+ Institute for Nanotechnology, University of Twente, The Netherlands. Following a career in academia and industry in a highly international landscape (France, Singapore, Ireland), she is currently leading the Group of Biointerfaces at FHNW and is a...

Cuong is an experienced Scientific Business Analyst at Sapio Sciences, leveraging a robust academic background with a PhD in molecular biology from Imperial College London and postdoctoral research at both Imperial College London and the Natural History Museum, London. At NatureMetrics, Cuong was...

Having completed a master’s degree in Immunology followed by 18 months of work experience in pediatric neuro-oncology setting at the University of Manitoba, Canada, Nazanin Tatari joined the laboratory of Dr. Sheila Singh, a world-renowned brain tumor researcher and a pediatric neurosurgeon, as a...

Dr. Jakub Tomala earned his Master Science degree and Ph.D., both in Immunology, at Charles University in Prague, Czech Republic. After completing a postdoctoral fellowship at Johns Hopkins University, School of Medicine, in 2018, Dr. Tomala became senior researcher in the Laboratory of...

Dr. Marco Traub has gained considerable experience in several research, management, and educational projects over the past 25 years. He is the founder of the Trans European Stem Cell Therapy Consortium (TESCT) and acts since 2005 as Chair of the TESCT consortium and as EU-Commission Expert...

​​​​​​​As the Commercial Director at Impact Medical Education, Gareth focuses mainly on providing senior strategic support and client counsel. With over 25 years of experience in healthcare communications, he has led medical communications agencies and teams, while also bringing expertise in...

Laura Unmuth is a PhD candidate in the Early Protein Supply & Characterization Department of Merck KGaA, supervised by Stefan Zielonka and in collaboration with the group of Prof. Dr. Harald Kolmar at the Technical University of Darmstadt. Her research work focuses on the generation and...

2015-2020: Scientist at Genentech,Since 2020: Head of Biology / VP, Biology and Translational Research at TubulisScientific training background: molecular cell biology, protein degradation, cellular protein homeostasis

Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. From 2001-2008, Bj?rn was team leader in the biotech company Pharmexa A/S, responsible for molecular cloning and expression of protein-based drug...

Hi! My name is Koen Wagner, from Leiden, The Netherlands. I am a multi-skilled biotechnologist with 10+ years experience in Antibody Drug Development. My areas of expertise include: Antibody Engineering, Drug Developability, Pre-Clinical Drug Development.   I graduated in Chemistry (M.Sc.) at...

Jörg Wischhusen studied biochemistry in Tübingen, Germany. During his thesis on mechanisms of immune escape in glioma (mentored by Michael Weller and Hans-Georg Rammensee) he performed early work in the field of experimental immune checkpoint blockade. In 2005 he was recruited as a junior research...

I graduated at the department of biochemistry at the Technical University of Darmstadt and did my phD in the field of antibody discovery and engineering in the working group of Prof. Harald Kolmar. I joined Merck in Darmstadt for a PostDoc project establishing microfluidic systems for antibody...

Che Yang is a specialist in protein engineering group at Novo Nordisk, with a particular focus on applying cutting-edge computational method and GenAI for design of mini-protein and antibody for the treatment of various diseases. He has been involved in scientific outreaching with emerging KOL in...

Dr. Yi-Ru Yu is currently a Senior Scientist at Pilatus Biosciences SA. He obtained his B.S. in Life Science and M.S. in Genomic Science from National Yang-Ming University in 2008. Dr. Yu then pursued a Ph.D. in Prof. Chun-Ming Chen's lab, where his research focused on the congenital diseases...

My passion are science and people. Hence,  it appealed to me to study medicine and following undergraduate studies in Berlin, I went into surgery in the UK and Germany,  and eventually I found my passion in surgical oncology, caring for patients with breast cancer, sarcoma, melanoma and many other...

Iwan Zimmermann is one of the founders and Chief Scientific Officer of Linkster Therapeutics. Iwan has over 12 years of experience with single domain antibodies and the biology of ion channels and transporters. Prior to co-founding Linkster Therapeutics, Iwan conducted research as platform leader...